Portfolio News

BD, Magnolia Medical Technologies announce Commercial Collaboration to help reduce blood culture contamination and improve testing accuracy

18 October 2022
< Back to News

FRANKLIN LAKES, N.J. (October 18, 2022) –BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Magnolia Medical Technologies, Inc., today announced a co-exclusive commercial agreement aimed at helping U.S. hospitals reduce blood culture contamination to help improve testing accuracy and ultimately improve clinical outcomes.

Under the agreement, BD and Magnolia Medical will both co-sell and co-market Magnolia Medical’s Steripath® and Steripath® Micro Initial Specimen Diversion Device® platforms, complementing the BD specimen collection portfolio, including BD Vacutainer® push button and BD Vacutainer® UltraTouch™ blood collection sets.

Read the full article here

Speak to us.

 

Contact Us.